Iron in kidney and heart failure: from theory to practice

International Urology and Nephrology

Volumn 50, Issue 3, 2018, Pages 481-493

  Yerlikaya, Aslihan ^a   Bulbul, Mustafa C ^a   Afsar, Baris ^b   Dagel, Tuncay ^a   Aslan, Gamze ^a   Voroneanu, Luminita ^c   Siriopol, Dimitire ^c   Covic, Adrian ^c   Kanbay, Mehmet ^a  

^a KOÇ UNIVERSITY   (Turkey)

^b SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

Author keywords

Heart failure; Iron deficiency; Iron replacement; Kidney disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INTERLEUKIN 1; INTERLEUKIN 6; IRON; PROTON PUMP INHIBITOR; TRANSFERRIN RECEPTOR; TUMOR NECROSIS FACTOR;

ACUTE CORONARY SYNDROME; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DNA SYNTHESIS; ECHOCARDIOGRAPHY; EXERCISE; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; IRON DEFICIENCY; IRON HOMEOSTASIS; LIFESTYLE MODIFICATION; MITOCHONDRIAL RESPIRATION; MORBIDITY; MORTALITY; MYOCARDITIS; PATHOPHYSIOLOGY; PROGNOSIS; QUALITY OF LIFE; REVIEW; SIX MINUTE WALK TEST; SYSTOLIC HEART FAILURE; VASCULAR REMODELING; CARDIORENAL SYNDROME; CHRONIC KIDNEY FAILURE; COMPLICATION; DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON METABOLISM DISORDER; PHYSIOLOGY;

ANEMIA, IRON-DEFICIENCY; CARDIO-RENAL SYNDROME; HEART FAILURE; HUMANS; IRON; IRON METABOLISM DISORDERS; QUALITY OF LIFE; RENAL INSUFFICIENCY, CHRONIC;

EID: 85029758938     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-017-1708-6     Document Type: Review

References (67)

1. Bui AL, Horwich TB, Fonarow GC (2011) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8(1):30–41
2. Cook C, Cole G, Asaria P, Jabbour R, Francis DP (2014) The annual global economic burden of heart failure. Int J Cardiol 171(3):368–376
3. Fitzsimons S, Doughty RN (2015) Iron deficiency in patients with heart failure. Eur Heart J Cardiovasc Pharmacother 1(1):58–64
4. Anker SD, von Haehling S (2004) Inflammatory mediators in chronic heart failure: an overview. Heart 90(4):464–470
5. Dickstein K, Authors/Task Force M, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P et al (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008‡. Eur J Heart Fail 10(10):933–989
6. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S (1994) Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 72(6):561–566
7. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D et al (1998) Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31(2):391–398
8. Niebauer J, Volk H-D, Kemp M, Dominguez M, Schumann RR, Rauchhaus M et al (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353(9167):1838–1842
9. Grabellus F, Levkau B, Sokoll A, Welp H, Schmid C, Deng MC et al (2002) Reversible activation of nuclear factor-κB in human end-stage heart failure after left ventricular mechanical support. Cardiovasc Res 53(1):124–130
10. Mann DL (2002) Inflammatory mediators and the failing heart. Circ Res 91(11):988–998
11. Drexler H, Hornig B (1999) Endothelial dysfunction in human disease. J Mol Cell Cardiol 31(1):51–60
12. Attanasio P, Katz SD, Anker SD (2010) Treatment with iron of patients with heart failure with and without anemia. Heart Fail Clin 6(3):305–312
13. Jankowska EA, Von Haehling S, Anker SD, Macdougall IC, Ponikowski P (2013) Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 34(11):816–829
14. Silverberg D, Iaina A, Wexler D, Schwartz D (2011) Iron repletion in heart failure patients. Hypertension 57(3):381–382
15. Ponka P (1999) Cellular iron metabolism. Kidney Int 55:S2–S11
16. Silverberg DS, Iaina A, Schwartz D, Wexler D (2011) Intravenous iron in heart failure: beyond targeting anemia. Curr Heart Fail Rep 8(1):14–21
17. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA (2011) Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 58(12):1241–1251
18. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B et al (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31(15):1872–1880
19. Hughes C, Woodside J, McGartland C, Roberts M, Nicholls D, McKeown P (2012) Nutritional intake and oxidative stress in chronic heart failure. Nutr Metabol Cardiovasc Dis 22(4):376–382
20. Lourenço BH, Vieira LP, Macedo A, Nakasato M, Marucci MDFN, Bocchi EA (2009) Nutritional status and adequacy of energy and nutrient intakes among heart failure patients. Arq Bras Cardiol 93(5):541–548
21. Dong F, Zhang X, Culver B, Chew HG, Kelley RO, Ren J (2005) Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci 109(3):277–286
22. Stugiewicz M, Tkaczyszyn M, Kasztura M, Banasiak W, Ponikowski P, Jankowska EA (2016) The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. Eur J Heart Fail 18(7):762–773
23. Goldstein D, Felzen B, Youdim M, Lotan R, Binah O (1996) Experimental iron deficiency in rats: mechanical and electrophysiological alterations in the cardiac muscle. Clin Sci 91(2):233–239
24. Zhu YI, Haas JD (1998) Altered metabolic response of iron-depleted nonanemic women during a 15-km time trial. J Appl Physiol 84(5):1768–1775
25. Haas JD, Brownlie T (2001) Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 131(2):676S–690S
26. Finch C, Miller L, Inamdar A, Person R, Seiler K, Mackler B (1976) Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction. J Clin Investig 58(2):447
27. Carson JL, Adamson JW (2010) Iron deficiency and heart disease: ironclad evidence? ASH Educ Program Book 2010(1):348–350
28. Maeder MT, Khammy O, dos Remedios C, Kaye DM (2011) Myocardial and systemic iron depletion in heart failure: implications for anemia accompanying heart failure. J Am Coll Cardiol 58(5):474–480
29. McMurray J, Ponikowski P (2011) Heart failure. J Am Coll Cardiol 58(5):481–482
30. Varma A, Appleton D, Nusca A, Lipinski M, Goudreau E, Cowley M et al (2010) Iron deficiency anemia and cardiac mortality in patients with left ventricular systolic dysfunction undergoing coronary stenting. Minerva Cardioangiol 58(1):1–10
31. Murphy C, Fitzsimons E, Jardine A, Sattar N, Mcmurray J (2007) 103 Routine assessment of iron status in all patients with heart failure may identify those at risk of developing anaemia. Eur J Heart Fail 6(S1):24
32. Rangel I, Gonçalves A, De Sousa C, Leite S, Campelo M, Martins E et al (2014) Iron deficiency status irrespective of anemia: a predictor of unfavorable outcome in chronic heart failure patients. Cardiology 128(4):320–326
33. de Silva R, Rigby AS, Witte KK, Nikitin NP, Tin L, Goode K et al (2006) Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am Cardiol 98(3):391–398
34. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG et al (2006) Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48(12):2485–2489
35. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W et al (2013) Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 165(4):575–582.e3
36. Yeo TJ, Yeo PSD, Ching-Chiew Wong R, Ong HY, Leong KTG, Jaufeerally F et al (2014) Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail 16(10):1125–1132
37. Cohen-Solal A, Damy T, Hanon O, Terbah M, Laperche T, Kerebel S et al (2014) High prevalence of iron deficiency in patients admitted for acute decompensated heart failure: a French study (Cardiofer). J Am Coll Cardiol 12(63):A779
38. Toblli JE, Lombraña A, Duarte P, Di Gennaro F (2007) Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50(17):1657–1665
39. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361(25):2436–2448
40. Filippatos G, Farmakis D, Colet JC, Dickstein K, Lüscher TF, Willenheimer R et al (2013) Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail 15(11):1267–1276
41. Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V et al (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36(11):657–668
42. Usmanov RI, Zueva EB, Silverberg DS, Shaked M (2008) Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 21(2):236–242
43. Gaber R, Kotb NA, Ghazy M, Nagy HM, Salama M, Elhendy A (2012) Tissue Doppler and strain rate imaging detect improvement of myocardial function in iron deficient patients with congestive heart failure after iron replacement therapy. Echocardiography. 29(1):13–18
44. Alexandrakis MG, Tsirakis G (2012) Anemia in heart failure patients. ISRN Hematol 2012:246915
45. Palazzuoli A, Ruocco G, Pellegrini M, De Gori C, Del Castillo G, Giordano N et al (2014) The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. Ther Clin Risk Manag 10:641–650
46. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H et al (2008) Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117(4):526–535
47. Kaldara-Papatheodorou EE, Terrovitis JV, Nanas JN (2010) Anemia in heart failure. Polskie Archiwum Medycyny Wewnętrznej 120(9):354–360
48. McCullough PA (2011) Micronutrients and cardiorenal disease: insights into novel assessments and treatment. Blood Purif 31(1–3):177–185
49. Silverberg DS (2011) The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome. Heart Fail Rev 16(6):609–614
50. Silverberg DS, Wexler D, Iaina A, Schwartz D (2011) Correction of iron deficiency in the cardiorenal syndrome. Int J Nephrol 2011:365301
51. Palazzuoli A, Antonelli G, Nuti R (2011) Anemia in cardio-renal syndrome: clinical impact and pathophysiologic mechanisms. Heart Fail Rev 16(6):603–607
52. Macdougall IC, Canaud B, de Francisco AL, Filippatos G, Ponikowski P, Silverberg D et al (2012) Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. Eur J Heart Fail 14(8):882–886
53. Klip IT, Jankowska EA, Enjuanes C, Voors AA, Banasiak W, Bruguera J et al (2014) The additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences. Eur J Heart Fail 16(6):655–662
54. Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Luscher T et al (2015) The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail 17(3):329–339
55. Toblli JE, Di Gennaro F, Rivas C (2015) Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron. Heart Lung Circ 24(7):686–695
56. Van Buren P, Velez RL, Vaziri ND, Zhou XJ (2012) Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int Urol Nephrol 44(2):499–507
57. Agarwal R, Vasavada N, Sachs NG, Chase S (2004) Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65(6):2279–2289
58. Vaziri ND (2013) Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 61(6):992–1000
59. Ishida JH, Johansen KL (2014) Iron and infection in hemodialysis patients. Semin Dial 27(1):26–36
60. Anderson LJ (2011) Assessment of iron overload with T2* magnetic resonance imaging. Prog Cardiovasc Dis 54(3):287–294
61. Nagao M, Matsuo Y, Kamitani T, Yonezawa M, Yamasaki Y, Kawanami S et al (2014) Quantification of myocardial iron deficiency in nonischemic heart failure by cardiac T2* magnetic resonance imaging. Am J Cardiol 113(6):1024–1030
62. Nagao M, Baba S, Yonezawa M, Yamasaki Y, Kamitani T, Isoda T et al (2015) Prediction of adverse cardiac events in dilated cardiomyopathy using cardiac T2* MRI and MIBG scintigraphy. Int J Cardiovasc Imaging 31(2):399–407
63. Ezekowitz JA, McAlister FA, Armstrong PW (2003) Anemia is common in heart failure and is associated with poor outcomes. Circulation 107(2):223–225
64. Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R et al (2005) Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26(21):2232–2237
65. Adlbrecht C, Kommata S, Hülsmann M, Szekeres T, Bieglmayer C, Strunk G et al (2008) Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body’s red cell volume. Eur Heart J 29(19):2343–2350
66. Bolger AP, Bartlett FR, Penston HS, O’Leary J, Pollock N, Kaprielian R et al (2006) Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48(6):1225–1227
67. Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabrò A et al (2006) Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152(6):1096.e9–1096.e15